Topos Bio

Topos Bio is a private, pre-clinical stage biotech leveraging a proprietary AI foundation model to drug intrinsically disordered proteins, a class of dynamic targets historically considered undruggable. The company has developed Topos-1, an all-atom foundation model for generating conformational ensembles of IDPs at speed, forming the core of its discovery platform. With a $10.5M seed round and partnerships with research institutes like Gladstone and Dalriada, Topos is positioning itself at the intersection of AI, structural biology, and small-molecule drug discovery. Its initial focus is on neurodegenerative diseases and oncology.

AI-native drug discovery platform centered on Topos-1, an all-atom foundation model for generating physically realistic conformational ensembles of intrinsically disordered proteins (IDPs) at high speed.

Topos Bio competes in the broad AI-driven drug discovery landscape with companies like Recursion, Exscientia, and Insilico Medicine, but its specific focus on intrinsically disordered proteins is a niche differentiation. It also competes with traditional structural biology and biophysics companies and academic groups working on IDP drug discovery. Its key competitive edge is the speed and scale of its ensemble-modeling foundation model.